Physician profile
Christopher W Lay
NPI 1891721403
$4,177.51
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $867 · 2020: $402 · 2021: $774 · 2022: $1,204 · 2023: $911 · 2024: $19.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $916 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $915.97 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $638.55 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $465.42 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $356.47 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $309.78 | 2019-2023 | Jardiance |
| Lilly USA, LLC | $255.81 | 2019-2023 | Mounjaro, Trulicity |
| Amgen INC. | $227.51 | 2019-2023 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $222.89 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $217.24 | 2019-2023 | |
| Glaxosmithkline, LLC. | $165.31 | 2021-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Amarin Pharma, INC. | $141.15 | 2019-2021 | |
| Pfizer INC. | $137.93 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $134.71 | 2022 | |
| Abbott Laboratories | $122.07 | 2019-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $120.13 | 2019-2021 | |
| Allergan, INC. | $106.52 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $102.29 | 2022-2023 | Quviviq |
| Esperion Therapeutics, INC. | $76.50 | 2021 | |
| Portola Pharmaceuticals, LLC | $53.13 | 2019 | |
| Sanofi-Aventis U.S. LLC | $38.72 | 2019 | |
| Exact Sciences Corporation | $37.01 | 2023 | Cologuard Collection Kit |
| Acerus Pharmaceuticals Corporation | $30.21 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $27.03 | 2021 | |
| Janssen Pharmaceuticals, INC | $26.87 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.58 | 2020 | |
| Eisai INC. | $20.10 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $19.88 | 2020 | |
| Organogenesis INC. | $18.63 | 2019 | |
| Antares Pharma, INC. | $17.67 | 2023 | Xyosted, Nocdurna, Tlando |
| Edwards Lifesciences Corporation | $17.65 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Ge Healthcare | $17.50 | 2019 | |
| Boston Scientific Corporation | $17.35 | 2023 | Watchman Access System |
| Medtronic Vascular, INC. | $14.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.